Proto Labs, Inc. filed its Form 10-Q with the U.S. Securities and Exchange Commission on October 29, 2026, covering the quarterly period ended September 30, 2026, and reporting year-over-year revenue and earnings growth for the third quarter.

Key Highlights

  • Q3 2026 Revenue: Proto Labs reported revenue of $154,318 thousand for the three months ended September 30, 2026, compared to $135,366 thousand in the same period of 2025.
  • Q3 2026 Net Income: Net income was $11,762 thousand for the third quarter of 2026, up from $7,216 thousand in Q3 2025.
  • Diluted EPS: Diluted net income per share was $0.48 for Q3 2026, compared to $0.30 in Q3 2025.
  • Nine-Month Revenue: Revenue for the nine months ended September 30, 2026 was $442,995 thousand, versus $396,634 thousand for the same period in 2025.
  • Total Assets: Total assets stood at $808,021 thousand as of September 30, 2026, up from $763,415 thousand at December 31, 2025.
  • Shareholders' Equity: Total shareholders' equity was $701,804 thousand at September 30, 2026, compared to $673,932 thousand at December 31, 2025.
  • Shares Outstanding: 23,871,875 shares of common stock were outstanding as of October 26, 2026.

Proto Labs Third-Quarter 2026 Financial Results and Balance Sheet Position

According to the filing, Proto Labs (NYSE:PRLB) generated revenue of $154,318 thousand in the three months ended September 30, 2026, producing gross profit of $68,663 thousand against cost of revenue of $85,655 thousand. Income from operations reached $14,441 thousand for the quarter, compared to $8,810 thousand in the third quarter of 2025. The company reported other income, net of $1,766 thousand, bringing income before income taxes to $16,207 thousand. After a provision for income taxes of $4,445 thousand, net income was $11,762 thousand.

For the nine months ended September 30, 2026, the filing disclosed revenue of $442,995 thousand and net income of $29,025 thousand, compared to $396,634 thousand in revenue and $15,242 thousand in net income for the same period in 2025. Basic net income per share for the nine-month period was $1.21, and diluted net income per share was $1.19, according to the filing. Total operating expenses for the nine months included $2,779 thousand in restructuring and transformation costs, with no such charge recorded in the comparable prior-year period.

The consolidated balance sheet as of September 30, 2026 showed cash and cash equivalents of $133,780 thousand, accounts receivable (net) of $99,256 thousand, and goodwill of $273,991 thousand, unchanged from December 31, 2025. The filing also disclosed that during the second and third quarters of 2026, the company repurchased shares of common stock, with repurchase activity totaling 68,553 shares in Q2 and 60,661 shares in Q3, at combined charges to retained earnings and paid-in capital of $5,036 thousand and $5,002 thousand, respectively. Accumulated other comprehensive loss was $(23,936) thousand at September 30, 2026, compared to $(20,976) thousand at December 31, 2025.

What Was Disclosed

Proto Labs filed its quarterly report for the period ended September 30, 2026, disclosing Q3 revenue of $154,318 thousand, net income of $11,762 thousand, diluted EPS of $0.48, total assets of $808,021 thousand, and 23,871,875 shares outstanding as of October 26, 2026.